Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease

20001,073 citationsJournal Article

Authors

David B. Badesch · Johns Hopkins University

Victor F. Tapson · Johns Hopkins University

Michael D. McGoon · Duke University

Bruce H. Brundage · Johns Hopkins University

Lewis J. Rubin · University of Maryland, Baltimore

Fredrick M. Wigley · University of Maryland, Baltimore

Stuart Rich

Abstract

Continuous epoprostenol therapy improves exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary hypertension due to the scleroderma spectrum of disease.

Topics & Keywords

Pulmonary Hypertension Research and Treatments Systemic Sclerosis and Related Diseases Vascular Anomalies and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Internal Medicine

Volume 132, Issue 6, pp. 425-434

DOI: 10.7326/0003-4819-132-6-200003210-00002

Field-Weighted Citation Impact: 50.84